Knowing earlier matters
Each person’s cancer is as unique as their fingerprint. Signatera™ is a MRD blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.
How Signatera™ helps patients through their treatment
Living scan to scan can sometimes create anxiety for patients. The question of relapse looms in the back of their mind: Did the treatment work? Is the cancer coming back?
Through shared decision making, patients can work closely with their care team to incorporate Signatera™ into their treatment plan to provide additional information for confident decision making. Listen to Brooks Bell tell her story of how she achieved peace of mind between scans using Signatera™.
Empowering the patient through Signatera™
Hear how Trevor is taking a more proactive approach with his health through Signatera™.
Living with colorectal cancer
Signatera™ is validated in multiple cancer types
I have colorectal cancer
If you have been diagnosed with colorectal cancer, learn more how to identify residual disease and detect relapse sooner with Signatera™ MRD testing
I am on immunotherapy
If you are undergoing immunotherapy and want to know how the Signatera™ MRD test can help monitor the effectiveness of your treatment
Is Signatera™ right for me?
If you have been diagnosed with cancer such as breast, ovarian, lung or melanoma and want to learn more how to identify residual disease and detect relapse sooner
Signatera™ is a blood MRD test used for cancer detection and surveillance. It is personalized for each patient. It is used for molecular residual disease assessment and for treatment response monitoring.
A doctor may order Signatera™ along with routine follow-up exams to determine whether:
- There are signs of cancer remaining in the body
- Treatment (e.g., chemotherapy, radiation) is working
- The cancer is recurring
How Signatera™ Works: a personalized and tumor informed approach to MRD surveillance
A one-time analysis of both blood and tissue determines your unique set of tumor mutations.
The MRD test is custom-built and personalized just for you, using your own tumor tissue.
Signatera™ MRD test detects small fragments of ctDNA each time it is ordered as part of your routine follow-up blood tests. Patients who are ctDNA positive by Signatera are more likely to relapse.
Understanding your Signatera™ test results
Your test results will either be positive or negative for the presence of tumor DNA in your blood. Your doctor will receive the test report and will be able to discuss your results and answer questions. These results provide additional insights and may help guide your treatment plan.
IMPORTANT: Negative ctDNA results may change over time. A negative MRD test result doesn’t guarantee that cancer will never be detected in the future. This is why ongoing monitoring with the Signatera™ test, as directed by your doctor, is recommended—for early detection of residual disease
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.